Validation of a symptom-based questionnaire for pediatric CNS demyelinating diseases

被引:3
作者
Waldman, Amy T. [1 ,3 ,4 ,5 ]
Yeshokumar, Anusha K. [6 ]
Lavery, Amy [1 ]
Liu, Geraldine [1 ]
Pineles, Stacy L. [7 ]
Repka, Michael X. [8 ]
Adang, Laura [1 ,3 ,4 ,5 ]
Narula, Sona [1 ,3 ,4 ,5 ]
Liu, Grant T. [2 ,3 ,5 ]
机构
[1] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Div Ophthalmol, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA
[4] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA
[5] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA
[8] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA
来源
JOURNAL OF AAPOS | 2019年 / 23卷 / 03期
关键词
MULTIPLE-SCLEROSIS; DISABILITY; CRITERIA;
D O I
10.1016/j.jaapos.2019.01.016
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE Optic neuritis is a manifestation of numerous neuroinflammatory disorders. Recognition of current and prior symptoms may facilitate identification of an underlying multifocal neurologic disease. The purpose of this study was to determine whether a symptom-based questionnaire could inform clinical decision making by identifying children with visual complaints who may have a systemic demyelinating disorder. METHODS Children with visual changes from non-demyelinating disease were compared with patients with confirmed pediatric-onset multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). Participants completed a 21-item questionnaire to capture their recent (<30 days) and remote (>30 days) symptoms of neurologic dysfunction. The questionnaire scores were compared using t tests, and the 95% confidence interval for each group was used to determine a threshold score suggesting demyelinating disease. RESULTS We enrolled 51 participants (30 females [59%]) with a mean age of 14.6 years (range, 4-21): 25 in the non-demyelinating disease group and 26 with MS/NMOSD. The mean questionnaire score for the non-demyelinating group was 5.0 points (95%CI, 3.3-6.9); for the MS/NMOSD group, 9.4 points (95% CI, 7.4-11.4) for the MS/NMOSD group (P < 0.002). Questionnaire results were dichotomized using a score of >= 7 as indicative of demyelinating disease, with 69% sensitivity and 72% specificity. An abbreviated questionnaire, using 8 questions that differed between groups, had a sensitivity of 65% and specificity (92%). CONCLUSIONS A symptom-based questionnaire is sensitive and specific for identifying children with CNS demyelinating disease and may be useful as a screening tool for children with vision complaints and possible demyelination.
引用
收藏
页码:157 / 158
页数:2
相关论文
共 50 条
[21]   Pediatric acquired CNS demyelinating syndromes Features associated with multiple sclerosis [J].
Hintzen, Rogier Q. ;
Dale, Russell C. ;
Neuteboom, Rinze F. ;
Mar, Soe ;
Banwell, Brenda .
NEUROLOGY, 2016, 87 (09) :S67-S73
[22]   Phosphorylated neurofilament heavy subunits as a marker of neurodegeneration in demyelinating diseases of the CNS [J].
A. A. Vorobyeva ;
V. V. Fominykh ;
M. V. Onufriev ;
M. N. Zakharova ;
N. V. Gulyaeva .
Neurochemical Journal, 2014, 8 :221-225
[23]   Non-infectious meningitis and CNS demyelinating diseases: A conceptual review [J].
Etemadifar, M. ;
Fereidan-Esfahani, M. ;
Sedaghat, N. ;
Kargaran, P. K. ;
Mansouri, A. R. ;
Abhari, A. P. ;
Aghababaei, A. ;
Jannesari, A. ;
Salari, M. ;
Ganjalikhani-Hakemi, M. ;
Nouri, H. .
REVUE NEUROLOGIQUE, 2023, 179 (06) :533-547
[24]   Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases [J].
Di Pauli, Franziska ;
Mader, Simone ;
Rostasy, Kevin ;
Schanda, Kathrin ;
Bajer-Kornek, Barbara ;
Ehling, Rainer ;
Deisenhammer, Florian ;
Reindl, Markus ;
Berger, Thomas .
CLINICAL IMMUNOLOGY, 2011, 138 (03) :247-254
[25]   Phosphorylated neurofilament heavy subunits as a marker of neurodegeneration in demyelinating diseases of the CNS [J].
Vorobyeva, A. A. ;
Fominykh, V. V. ;
Onufriev, M. V. ;
Zakharova, M. N. ;
Gulyaeva, N. V. .
NEUROCHEMICAL JOURNAL, 2014, 8 (03) :221-225
[26]   Atypical Pediatric Demyelinating Diseases of the Central Nervous System [J].
Regina M. Troxell ;
Alison Christy .
Current Neurology and Neuroscience Reports, 2019, 19
[27]   Atypical Pediatric Demyelinating Diseases of the Central Nervous System [J].
Troxell, Regina M. ;
Christy, Alison .
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2019, 19 (12)
[28]   Digital symbol-digit modalities test with modified flexible protocols in patients with CNS demyelinating diseases [J].
Seo, Dayoung ;
So, Jeong Min ;
Kim, Jiyon ;
Jung, Heejae ;
Jang, Inhye ;
Kim, Hyunjin ;
Kang, Dong-Wha ;
Lim, Young-Min ;
Choi, Jaesoon ;
Lee, Eun-Jae .
SCIENTIFIC REPORTS, 2024, 14 (01)
[29]   New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases [J].
Di Pauli, Franziska ;
Reindl, Markus ;
Berger, Thomas .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 22 :35-37
[30]   Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases [J].
Gredler, Viktoria ;
Mader, Simone ;
Schanda, Kathrin ;
Hegen, Harald ;
Di Pauli, Franziska ;
Kuenz, Bettina ;
Deisenhammer, Florian ;
Berger, Thomas ;
Reindl, Markus ;
Lutterotti, Andreas .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 328 (1-2) :77-82